Don't get the drop either. Thought we'd see a couple more percent up today after they killed earnings and will likely do so for the foreseeable future.
Not really imo, most sane people realized long ago that DNDN was dead. What it WILL help with is getting rid of the lunatic fringe DNDN cultist on this board.
And Pcyc with their blockbuster cancer drug Imbruvica (which I have owned all the way from $2.00)
I also own mdvn, acad and gild in my top picks, outside of bios Swks has done well for me but at the moment I am very excited about MDVN, the potential is so huge.
Sentiment: Strong Buy
Exactly how many alias do you have to keep posting this Riceen garbage and responding to your own posts? Does your shrink know about all your different personalities?
Clever. "Most important website."
Here is transcript from the "medical express" website. I will post 2nd half as reply.
Possible new weapon found for fighting some types of breast cancer
Researchers believe they have discovered one reason why some women with estrogen receptor-positive breast cancer may respond poorly or only temporarily to estrogen-blocking drugs such as tamoxifen. Results of a new study, which was presented Saturday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago, point to a previously unrecognized role of the androgen receptor.
Although this receptor (protein) is expressed in nearly all prostate cancers, it also is expressed in most breast cancers. Now scientists have found that estrogen receptor alpha—a main driver of estrogen-fueled breast cancer—may rely on the androgen receptor for its function.
In a study funded by the U.S. Department of Defense Breast Cancer Research Program, Jennifer Richer, PhD, from the University of Colorado Anschutz Medical Campus in Aurora, and her colleagues studied 192 women with estrogen receptor-positive breast cancers. They found that women were 4.4 times more likely to have a cancer recurrence during tamoxifen treatment when their main tumor had a high ratio (2:1 or greater) of androgen receptor-positive cells to estrogen receptor-positive cells.
"Women with breast cancer do not routinely receive testing for the androgen receptor," Richer commented.
The investigators hypothesized that maximal estrogen receptor activity depends on the androgen receptor's nuclear localization. This process, Richer said, involves the receptor moving itself and the hormone molecule, to which it is bound, inside the nucleus of a cell, where the receptor "does its important business."
Sentiment: Strong Buy
Is the study you're talking about be found by using the most pop. search engine and looking for:
breast cancer research 16/1/R7
That will pull up both the abstract and complete study released in Jan. '14 that says this:
".....enzalutamide uniquely inhibited estradiol (E2)-mediated proliferation of ER+/AR + breast cancer cells. In MCF7 xenografts (ER+/AR+) enzalutamide inhibited E2-driven tumor growth as effectively as tamoxifen by decreasing proliferation. Enzalutamide also inhibited DHT- driven tumor growth in both ER positive (MCF7) and negative (MDA-MB-453) xenografts, but did so by increasing apoptosis., ....... ... This preclinical study supports the initiation of clinical studies evaluating enzalutamide for treatment of AR+ tumors regardless of ER status, since it blocks both androgen- and estrogen- mediated tumor growth.
One month from now we have the San Antonio Breast Cancer Symposium and that will let us know if Xtandi has a role in breast cancer treatment.
I doubt it, you might get a bit of more detailed analysis of the pipeline and future drivers, but listening to the idiots asking the questions on the conference call, most of them were bean counters, not scientist.
Analysts don't like to get too far over their skis, we got a round of price raises this earnings and will likely get another one after the next quarters numbers. Especially if the San Antonio Breast Cancer Symposium starting Dec. 9th has some favorable info on an entirely new use for enzalutamide.
There are a few small shops that do good work in the biotech field but most of the big shops are very hit and miss. Check out this guy's twitter feed dougheuringaria he and a few others on twitter collect some great info. Here's another great twitter feed AndyBiotech for biotech investors. There are some others you can track them down by following the conversations on the first two feeds.
not the ones they put out there free, I mean the ones that companies like Deutsche bank charge brokers $50k a shot for. I bet the true target on mdvn is closer to $150.
It was a search in Kiplinger's and Riceen. His article appeared. I got to read in the financial Currior predictions predictions an article where Riceen claims that MDVN could go to $123.00 in two weeks. It was a great letter.
Sentiment: Strong Buy
I was up a lot. I was strongly thinking of taking my profits and run, then in read the "Riceen Letter". He said to hold and don't do a thing until after earnings. By listening to Riceen, I could add a few more thousand dollars to my bottom line.